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Background: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy
drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA
damage response or DNA replication defects.
Methods: Here we describe the cellular effects of the pharmacological inhibition of the checkpoint kinase Chk1 by
the novel inhibitor V158411 in triple-negative breast cancer and ovarian cancer. Cytotoxicity, the effect on DNA
damage response and cell cycle along with the ability to potentiate gemcitabine and cisplatin cytotoxicity in
cultured cells was investigated. Western blotting of proteins involved in DNA repair, checkpoint activation, cell cycle
and apoptosis was used to identify potential predictive biomarkers of Chk1 inhibitor sensitivity.
Results: The Chk1 inhibitors V158411, PF-477736 and AZD7762 potently inhibited the proliferation of triple-negative
breast cancer cells as well as ovarian cancer cells, and these cell lines were sensitive compared to ER positive
breast and other solid cancer cells lines. Inhibition of Chk1 in these sensitive cell lines induced DNA damage and
caspase-3/7 dependent apoptosis. Western blot profiling identified pChk1 (S296) as a predictive biomarker of Chk1
inhibitor sensitivity in ovarian and triple-negative breast cancer and pH2AX (S139) in luminal breast cancer.
Conclusions: This finding suggests that Chk1 inhibitors either as single agents or in combination chemotherapy
represents a viable therapeutic option for the treatment of triple-negative breast cancer. pChk1 (S296) tumor expression
levels could serve as a useful biomarker to stratify patients who might benefit from Chk1 inhibitor therapy.
Keywords: Chk1, Breast cancer, Ovarian cancer, V158411, DNA repair, Triple-negativeBackground
Breast cancer is the most common cancer affecting wo-
men and the second most common cause of death due
to cancer [1]. This highly heterogeneous disease has been
classified into various subgroups (namely luminal, HER2
positive, basal-like and normal breast) based on gene
expression profiles and phenotypic characteristics [2].
Triple-negative breast cancer (TNBC) is characterized
by a lack of expression of estrogen receptor (ER), pro-
gesterone receptor (PR) and ErbB-2/human epidermal
growth factor receptor 2 (HER2) [3,4]. TNBC shares many
of the gene expression profiles and phenotypical features
of basal-like breast cancer [5,6]. The prognosis for breast* Correspondence: a.massey@vernalis.com
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unless otherwise stated.cancer patients with basal-like disease, including TNBC, is
generally much poorer than those of other sub-groups
due to the aggressive nature of this sub-group. Whilst
basal-like and triple-negative breast cancers have been
demonstrated to be chemo-sensitive to neoadjuvant ther-
apy, the relapse rates are more aggressive resulting in a
worse overall survival [7,8]. Unlike ER, PR or HER2 posi-
tive tumors where clear molecular targets for therapeutic
intervention exist, identifying specific molecular targets
for TNBC has proved more elusive.
Breast tumors arising from hereditary BRCA mutation
carriers are mostly triple-negative and share a striking
resemblance to sporadic basal-like and triple-negative
breast cancers suggesting that TNBC might bear defects
in DNA repair thereby endowing a degree of “BRCAness”
on these cancers [9]. BRCA mutant cell lines have beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cisplatin [10] as well as inhibitors of the repair protein
poly (ADP-ribose) polymerase (PARP), a key component
of the base excision DNA repair pathway [11,12]. Recent
studies have shown that basal-like TNBC cell lines are also
sensitive to PARP inhibitors and cytotoxic chemotherapy
drugs such as gemcitabine and cisplatin [13,14]. Inhib-
ition of PARP in cancer cells with defects in DNA double
strand break (DSB) repair pathways (such as BRCA mu-
tant breast cancer) results in an accumulation of single
strand breaks (SSBs) leading to replication fork collapse,
DSB generation and cell death. This reliance on alternative
DNA repair pathways may make cancers such as TNBC
sensitive to other agents that target DNA damage res-
ponse pathways.
The DNA damage signaling response pathway (DDR)
is activated by DNA breaks induced by a variety of en-
dogenous and external insults including therapies cur-
rently used for the treatment of cancer such as ionizing
radiation and cytotoxic chemotherapeutic agents such as
gemcitabine, irinotecan and cisplatin. Activation of the
DDR results in a number of cellular responses including
checkpoint activation and cell cycle arrest, initiation of
DNA repair, regulation of transcription and apoptosis
[15,16]. The serine-threonine checkpoint kinases Chk1
and Chk2 are activated by the ATR and ATM kinases in
response to DNA breaks and form the key link between
the sensing kinases ATR/ATM and the cell cycle ma-
chinery [17]. Phosphorylation of Chk1 leads to check-
point activation and cell cycle arrest at the G1/S, intra S
or G2/M phases. Despite their similarity in name, Chk1
and Chk2 differ substantially in the structure of their
kinase pocket [18,19] and in their cellular function with
Chk1 suggested to be the major component responsible
for responses to DNA damage. Inhibiting Chk1 follow-
ing genotoxic stress (such as that induced by cytotoxic
chemotherapy) results in checkpoint abrogation, inhib-
ition of DNA repair and induction of cell death in cells
with a defective p53 response [20,21]. Small molecule in-
hibitors of predominantly the Chk1 kinase have been
readily sought as a mechanism through which the anti-
tumor activity of cytotoxic chemotherapeutics may be
increased whilst sparing normal cells [22,23]. This ap-
proach is currently being tested in the clinic with a
variety of agents including LY2603618 [24], GDC-0425,
GDC-0575, MK-8776 [25], PF-477736 [26] and AZD7762
[27] in combination with a range of standard of care che-
motherapy drugs.
It has also been postulated that DNA damage response
checkpoints and especially Chk1 kinase activity may be
critical for the normal replication of cancer cell lines with
specific underlying defects in DNA repair or DNA da-
mage response pathways, or DNA replication defects.
For example, the Fanconi Anaemia (FA) repair pathway isresponsible for repairing crosslinked DNA and maintain-
ing chromosomal stability [28]. FA deficient cell lines were
found to be sensitive to Chk1 silencing by siRNA com-
pared to FA proficient cells [29]. We hypothesized that,
given their likeness to DNA repair compromised heredi-
tary BRCA mutated breast cancers, triple-negative breast
cancer may be sensitive to cell killing by Chk1 inhibitors.
V158411 is a novel, potent, selective inhibitor of re-
combinant Chk1 and Chk2 kinases in vitro with IC50s of
3.5 and 2.5nM respectively [30]. In p53 defective HT29
cells, V158411 inhibited the etoposide induced auto-
phosphorylation of Chk1 on Ser296 with an IC50 of 48
nM and Chk2 on Ser516 with an IC50 of 904 nM indi-
cating a 19-fold cellular selectivity for Chk1 over Chk2.
V158411 potentiated cytotoxic chemotherapy in p53
defective cancer cells in vitro and in vivo. We therefore
evaluated the single agent cytotoxic potential of V158411
against a panel of solid cancer cell lines including those
derived from breast and ovarian cancer. We further pro-
filed the panel of cell lines to understand and identify
potential biomarkers predictive of response to Chk1 inhib-
ition. The data provides a preclinical rationale to support
the clinical testing of Chk1 inhibitors as single agents and
in combination with cytotoxic chemotherapy in patients
with triple-negative breast cancer.
Methods
Cell culture and cytotoxicity assay
All cells were obtained from the American Type Culture
Collection and cultured in DMEM, RPMI or McCoys 5a
containing 10% FCS (Invitrogen). The cytotoxicity of
V158411 was determined following exposure of cells in
96 well plates to a 10-point titration for 72 hours. Cell
proliferation was determined using sulphorhodamine B
(Sigma) staining following protein precipitation with
10% TCA. For cell counts, cells were seeded in 6 well
plates and counted following trypsinisation after 72 hours
using a haemocytometer with trypan blue staining.
Compounds
V158411 was synthesized according to the method de-
scribed in [30] and prepared as a 20 mM DMSO stock in
DMSO. Solid stocks were purchased from the indicated
suppliers and prepared as concentrated stock solutions in
the appropriate solvent: gemcitabine (Apin Chemicals
Inc), 20 mM in H2O; cisplatin (Selleckchem), 3.33 mM
in 1% NaCl in H2O; oxaliplatin (Tocris), 5 mM in
H2O; carboplatin (Tocris), 25 mM in H2O; PF-477736
(Selleckchem), 20 mM in DMSO and AZD7762 (Axon
Medchem), 20 mM in DMSO.
Determination of caspase-3/7 dependent apoptosis
Cells were seeded in 96 well plates and treated with 10-
times the GI50 of V158411 for 24 or 48 hours. Caspase-3/
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7 luminescence kit (Promega).
Antibodies and western blotting
Anti-pHistone H3 (S10) was obtained from Millipore;
Chk1, pChk1 (S317), pChk1 (S345), pChk2, pChk2 (T68),
pCdc25c (S216), 53BP1, Cdc2, pCdc2 (Y15), Cyclin B1,
D1 and E, PARP, pERK1/2, ERK 1/2, AKT, pAKT (S473),
Bcl-XL, GAPDH and pH2AX (S139) from Cell Signaling
Technologies; pChk1 (S296), FANCF and FANCD2 from
Abcam, and Bcl-2 and Mcl-1 from Santa Cruz. Treated
and untreated cells were washed once with PBS and lysed
in RIPA buffer containing protease and phosphatase in-
hibitor cocktails (Roche). Protein concentration was deter-
mined using BCA kit (Pierce). Equal amounts of lysate
were separated by SDS-PAGE and western blot analysis
conducted using the antibodies indicated above.
Flow cytometry
Cells were seeded in 6 well plates and subsequently trea-
ted with the indicated concentrations of V158411 for 24
or 48 hours. All cells were harvested, fixed in 70% ethanol
and stained with propidium iodide/RNase A. Cell cy-
cle profiles were examined by flow cytometry using a
FACSArray cytometer (BD) and FACSDiva software (BD).
Potentiation assays
5x103 cells per well were seeded in 96 well plates and in-
cubated overnight. Cells were treated with a 10-point ti-
tration of gemcitabine or cisplatin in the presence of a
fixed concentration of V158411 for 72 hours. The effect
on cell proliferation was determined using a CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS,
Promega).
Ethical approval
None of the research in this manuscript involved human
subjects, human material, or human data, or used regu-
lated vertebrates or invertebrates.
Results
Pharmacological abrogation of Chk1 activity inhibits cell
proliferation and induces caspase activation in human
triple-negative breast and ovarian cancer cell lines
Sporadic basal-like or triple-negative breast cancers
strongly resemble breast cancers originating from her-
editary BRCA defective patients and may harbor BRCA-
mimetic defects in DNA repair pathways. To test the
hypothesis that triple-negative breast cancers are sensitive
to Chk1 inhibitors in the absence of cytotoxic chemother-
apy agents, a panel of sporadic triple-negative and luminal
breast cancer cell lines [31] as well as several ovarian can-
cer cell lines were tested for their sensitivity to V158411and compared against a panel of cell lines derived from
cancers of the lung, colon or prostate.
The TNBC cell lines exhibited increased sensitivity
to V158411 compared to either the ER or HER2 posi-
tive breast cancer cell lines BT474 and MCF7 as well
as a range of colon, lung and prostate cancer cell lines
(Figure 1A and Table 1). The exception was the HER2
positive, ER negative breast cancer line SKBr3 which ex-
hibited V158411 sensitivity equivalent to the TNBC cell
lines. In addition, two out of the three ovarian cell lines
tested exhibited increased sensitivity to V158411. We con-
firmed the sensitivity of TNBC and ovarian cancer cell
lines to Chk1 inhibition with two additional Chk1 inhibi-
tors PF-477736 [26] and AZD7762 [27]. As observed with
V158411, the TNBC and ovarian cell lines exhibited in-
creased sensitivity to these two agents compared to the
MCF7 and BT474 breast cell lines (Figure 1B). There
was a strong correlation between cell line sensitivity to
V158411 and PF-477736 (R2 = 0.899, Figure 1C). The cor-
relation between V158411 and AZD7762, and PF-477736
and AZD7762 sensitivity was less strong (R2 = 0.653 and
0.635 respectively) and may be due to the reduced kinase
selectivity of AZD7762 compared to V158411 and PF-
477736. Sensitivity to V158411 was independent of p53
or kRas mutational status (Figure 1D). Likewise, the in-
creased sensitivity of the triple-negative breast and ovarian
cancer cell lines to V158411 did not correlate with in-
creased sensitivity to the DNA damaging agent cisplatin
(R2 = 0.018, Figure 1E). We compared the sensitivity of
cell lines to V158411 and a variety of DNA damaging
drugs using data from the Genomics of Drug Sensitivity in
Cancer data set (Release 4, [32]). Again, there was no cor-
relation between sensitivity to V158411 and camptothecin,
cytarabine, doxorubicin, etoposide, cisplatin, gemcitabine,
olaparib or mitomycin C (R2 < 0.1). Inhibition of the estro-
gen receptor with 4-hydroxytamoxifen did not increase
the sensitivity of the ER positive BT474 and MCF7 cell
lines to Chk1 inhibition (Figure 1F). Treatment with
V158411 led to a reduction in cell viability in sensi-
tive TNBC and ovarian cell lines (Figure 2A). This reduc-
tion in viability was accompanied by V158411 induced
caspase-3/7 dependent apoptosis in the sensitive cell lines
(Figure 2B and C). The resistance of the BT474 and
MCF7 cell lines appeared independent of p53 mutational
status and ER or HER2 receptor expression status.
Chk1 inhibition induces Chk1 degradation and H2AX
phosphorylation
The effect of V158411 on the Chk1 DNA damage res-
ponse pathway in MDA-MB-468 and SKOV-3 cells was
determined. Treatment of either cell line with V158411
for 24 hours resulted in decreased Chk1 autophospho-
rylation (on serine 296). This inhibition of Chk1 correlated



















































































































































































































































































Figure 1 Inhibition of Chk1 inhibits cell proliferation in human triple-negative breast and ovarian cancer cell lines. A. Human tumor cell
lines were treated with the Chk1 inhibitor V158411 for 72 hours and the cell number determined using the SRB assay. Values are the average of
at least four independent determinations ± SD. B. Breast and ovarian cell lines were exposed to the Chk1 inhibitors V158411, PF-477736 and
AZD7762 for 72 hours. Cell number was determined by SRB assay. Values are the mean ± SD for n ≥ 4. C. Comparison of cell line sensitivity to
V158411 and PF-477736. D. Sensitivity to V158411 was independent of p53 mutational status. The p53 mutation status was determined from the
Cancer Genome Project. E. Comparison of the sensitivity of breast (square), ovarian (triangle), colon (diamond) and lung (circle) cell lines to growth
inhibition by V158411 and cisplatin. F. ER-positive breast cancer cells were exposed to V158411 in the presence of 0 or 10 μM 4-hyrdroxytamoxifen
(4-OHT) for 72 hours and the cell number (GI50) determined by SRB assay. The values are the average of 4 determinations ± SD and the fold difference
between 0 and 10 μM 4-OHT shown.
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tion on serine 317 and 345 and increased pH2AX (S139)
(Figure 3A). Treatment of all five TNBC cell lines or the
sensitive SKOV-3 ovarian cell line with V158411 for
24 hours led to a dose dependent decrease in Chk1protein levels and a concomitant increase in the amount
of H2AX phosphorylated at Ser139 (Figure 3A). The dose
at which V158411 decreased Chk1 protein levels and
increased H2AX phosphorylation correlated closely with
the sensitivity of the cell line to V158411 toxicity. In
Table 1 Breast and ovarian cell lines used in this study and their sensitivity to V158411
Tissue Cell line Gene cluster ER PR HER2 TP53 GI50 (μM)
Breast BT474 Lu + + + Mut 2.6 ± 1.3
HCC1937 BaA - - Mut 0.11 ± 0.01
MCF7 Lu + + WT 2.0 ± 0.5
MDA-MB-157 BaB - - Mut 0.25 ± 0.02
MDA-MB-231 BaB - - Mut 0.18 ± 0.02
MDA-MB-453 Lu - - WT 0.019 ± 0.005
MDA-MB-468 BaA - - Mut 0.31 ± 0.02
SKBr3 Lu - - + Mut 0.022 ± 0.003
Ovarian A2780 - - WT 0.39 ± 0.05
ES-2 Mut 3.1 ± 1.2
SKOV-3 - + Mut 0.06 ± 0.02
ER, estrogen receptor; PR, progesterone receptor; BaA, Basal A; BaB, Basal B; Lu, Luminal; WT, wild type; Mut, mutant; breast data from [31]. Values represent the












































































































































Figure 2 V158411 reduces cell viability and induces caspase-3/7 dependent apoptosis. A. V158411 inhibits the viability of triple-negative
breast and ovarian carcinoma cells. Cells were exposed to 5 or 10-times the GI50 of V158411 for 72 hours and the cell viability determined using
trypan blue staining. Values are the average of ≥4 determinations ± SD. B. Caspase-3/7 dependent apoptosis is induced in triple-negative breast
and ovarian carcinoma cell lines in vitro. Cells were exposed to 10-times the GI50 of V158411 for 24 or 48 hours and caspase activity determined
using a homogenous caspase-3/7 activation kit. Values are the average of 3 replicates ± SD. C. Caspase-3/7 activation was confirmed by
immunoblotting in SKOV-3 cells treated for 48 hours with the indicated concentrations of V158411. FL, full length; CL, cleaved.

















































































































































Figure 3 Chk1 inhibition by V158411 induces Chk1 degradation and H2AX phosphorylation. Triple-negative breast or ovarian cancer cells
(A) or luminal breast cancer cell lines (B) were exposed to the indicated concentrations of V158411 for 24 hours. C. MDA-MB-468 TNBC cells were
treated with 1 μM V158411 for 0 to 24 hours. Protein changes were assessed by immunoblotting.
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lines BT474 and MCF7, treatment with an equitoxic dose
of V158411 resulted in a decrease in Chk1 protein levels
but not a subsequent increase in H2AX phosphorylation
(Figure 3B). The response of the sensitive luminal breast
cancer cell line SKBr3 mirrored that of the sensitive
TNBC cell lines. A time course of V158411 treatment in
MDA-MB-468 cells indicated that inhibition of Chk1
autophosphorylation (S296) occurred rapidly (in under
1 hour) and that activation of ATR (as measured by in-
creased phosphorylation of Chk1 at S317/S345) was coin-
cidental with inhibition of Chk1. Maximal Chk1 reduction
and H2AX phosphorylation was delayed compared to
Chk1 inhibition requiring 24 hours for the maximal re-
sponse to be observed (Figure 3C).
Chk1 inhibition induces cell cycle arrest and DNA
fragmentation
Treatment of breast and ovarian cancer cell lines with
V158411 lead to dramatic changes in the cell cycle dis-
tribution of the treated cells. In both sensitive and resis-
tant cell lines, V158411 treatment massively decreased
the fraction of cells in G1. The resistant luminal breast
cancer lines BT474 and MCF7 responded by arresting in
G2/M whilst in the sensitive TNBC and luminal SKBr3
cell lines, the decrease in G1 correlated with an increase
in sub-G1 or greater than G2/M DNA content indicative
of an increase in DNA fragmentation and chromosomal
breakages (Figure 4A). In the two sensitive ovarian cell
lines, V158411 again dramatically reduced the G1 frac-
tion of cells and increased the fraction of cells with
fragmented DNA (sub-G1 or > G2/M) (Figure 4B). Over-
all, the sensitive TNBC and SKBr3 cell lines exhibited
the greatest increase in sub-G1 DNA content following
V158411 treatment (Figure 4C). To evaluate if cells were
progressing into mitosis and undergoing death via mitotic
catastrophe, we utilized nocodazole to trap cells in mitosis
following V158411 treatment. Nocodazole increased the
fraction of MDA-MB-231, MDA-MB-468 and BT474 cells
in mitosis as evidenced by an increase in the levels of
phH3 (S10). However, treatment with V158411 plus noco-
dazole did not lead to an increase in the number of mi-
totic cells compared to V158411 alone (Figure 4D). In the
resistant BT474 cells but not the two sensitive TNBC cell
lines, V158411 treatment reduced the phosphorylation of
Cdc2 on Tyr15 and is consistent with the G2/M arrest ob-
served in this cell line.
Western blot profiling of breast and ovarian cell lines
identified Chk1 Ser296 phosphorylation as a predictive
biomarker of sensitivity
Identifying biomarkers that potentially predict for sensitiv-
ity to single agent Chk1 inhibition is important for trans-
lating the therapy into the right patients in the clinic. Weexamined the expression levels of a variety of checkpoint,
cell cycle, apoptosis and DNA repair associated proteins
across the panel of sensitive and resistant ovarian cell
lines. The expression levels of these proteins, following
immunoblot analysis, is illustrated in Figure 5. Two mar-
kers were identified as correlating with increased sensi-
tivity to V158411 cytotoxicity. All the TNBC cell lines
exhibited high levels of Chk1 phosphorylated on Ser296
compared to the ER positive breast cancer cell lines. In
the sensitive luminal breast cancer cell line SKBr3, the en-
dogenous levels of H2AX phosphorylated on Ser139 was
much higher compared to all other cell lines. In the ovar-
ian cell lines, the sensitive A2780 and SKOV-3 as well as
the resistant ES-2 cell line exhibited high levels of en-
dogenous pChk1 (S296). Chk1 was expressed in variable
amounts across all eleven cell lines examined whilst the
levels of Chk1 phosphorylated on the ATM/ATR sites
Ser317 and 345 was virtually undetectable. The increased
levels of Chk1 (S296) and H2AX (S139) phosphorylation
are consistent with underlying defects in DNA repair and/
or replication. Analysis of other proteins associated with
DNA replication or the DDR response did not identify a
consistent mechanism for Chk1 activation.
V158411 potentiates cytotoxic chemotherapy in TNBC
and ovarian cancer cell lines
The ability of V158411 to potentiate the cytotoxicity of a
variety of cytotoxic chemotherapeutic drugs was assessed
across a panel of luminal breast cancer and TNBC cell
lines. V158411 effectively potentiated the growth inhibi-
tory activity of gemcitabine and cisplatin in the panel of
p53-defective but not p53-proficient cell lines (Figure 6A
and B). As has been seen with other Chk1 inhibitors, the
most robust potentiation was observed with gemcitabine
across the range of cell lines. For gemcitabine, not only
did V158411 reduce the EC50 of the chemotherapeutic
agent but it also increased the fraction of cells killed. In
the ovarian carcinoma cell line SKOV-3, V158411 mod-
estly potentiated the cytotoxic activity of carboplatin and
cisplatin but not oxaliplatin (Figure 6C). Western blotting
analysis revealed that all three platinum drugs increased
the phosphorylation of Chk1 on Ser296 but only the
combination of cisplatin with V158411 robustly induced
H2AX phosphorylation on Ser139 (Figure 6D). As well as
exhibiting single agent activity against TNBC and ovarian
cancer cell lines, V158411 potentiated the cytotoxicity of
chemotherapeutic drugs in these tumor types suggesting
that Chk1 inhibitors either alone or in combination could
be a viable treatment option in these tumor types.
Discussion
Multiple Chk1 inhibitors are currently undergoing clinical
testing in combination with a variety of cytotoxic chemo-
















































































































































































Figure 4 Cell cycle changes associated with Chk1 inhibition in breast and ovarian cells. Cell cycle profiles of TNBC (A) or ovarian cancer (B)
cells were determined by PI staining following treatment with the indicated concentrations of V158411 for 24 hours. C. The fraction of cells with
a sub-G1 DNA content was quantitated from the cell cycle profiles following 48 hour incubation. D. MDA-MB-231, MDA-MB-468 or BT474 cells
were treated with 1 μM V158411 in the presence or absence of 0.5 μM nocodazole for 24 hours. Protein levels were subsequently assessed by
western blotting.
















































































Figure 5 Western blot analysis of breast and ovarian cell lines.
Untreated whole cell protein extracts were prepared from the
indicated cell lines and the expression levels of various protein
markers determined by western blotting.
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creasing the systemic toxicity of these drugs. Recent work
using loss-of-function siRNA screens or small molecule
Chk1 inhibitors have begun to identify tumor types where
Chk1 is critical for cancer cell proliferation and/or viability
in the absence of a DNA damaging chemotherapeutic
agent. To date, neuroblastoma [33], melanoma [34], Myc
driven lymphomas [35,36], leukemia and lymphoma cell
lines [37,38] and Fanconi’s Anemia cells [29] have been
identified to be Chk1 kinase dependent. This suggests thatthere may be subsets of cancers for which a Chk1 inhibi-
tor, administered as a single agent, could be a useful thera-
peutic option.
We postulated that cancers with underlying defects in
DNA repair, DNA damage response or DNA replication
may be suitable candidates for single agent Chk1 inhibi-
tor therapy. Spontaneous triple-negative breast cancer
shares many of the characteristics of tumors derived from
patients carrying mutations in the BRCA gene. BRCA is
known to be involved in a variety of DNA repair pathways
such as homologous recombination and base excision
repair and are exquisitely sensitive to inhibitors of poly
(ADP-ribose) polymerase. Recent reports have demons-
trated the sensitivity of TNBC to PARP inhibitors as well
as DNA damaging cytotoxic agents such as gemcitabine
and cisplatin [14]. TNBCs have been shown to have
reduced expression of DNA repair genes involved in
base excision repair, nucleotide excision repair and the
Fanconi’s Anemia repair pathways [39]. This suggests
that like cancers that arise in BRCA mutation carriers,
spontaneous TNBCs may harbor underlying defects in
DNA repair and we hypothesized that this cancer sub-
type may be a suitable candidate for single agent Chk1
inhibitor therapy.
This hypothesis was substantiated in a screen of 26
solid cancer cell lines where TNBC cancer cell lines were
among the most sensitive to growth inhibition by the
novel, selective Chk1 inhibitor V158411. Even though
V158411 is an extremely selective inhibitor of Chk1, it is
difficult to ascertain the absolute selectivity of any small
molecule kinase inhibitor. To confirm this observation,
two structurally unrelated Chk1 kinase inhibitors PF-
477736 [26] and AZD7762 [27] potently inhibited the
proliferation of TNBC breast cancer cell lines compared
to two ER-positive cell lines suggesting that the anti-
proliferative effects observed were due to Chk1 inhi-
bition and not the inhibition of an off target kinase.
However, the sensitivity to the Chk1 inhibitors was
not just limited to the TNBC cell lines as the HER2-
postive, ER-negative SKBr3 breast cancer cell line and
the SKOV-3 ovarian cancer cell line (HER2-positve, ER-
positive but estrogen insensitive [40]) were among the
most sensitive cell lines to Chk1 inhibitor induced cell
death. These results have recently been confirmed by
another study demonstrating that four TNBC cell lines
(including HCC1937, MDA-MB-157 and MDA-MB-468
used in this study) had reduced viability following Chk1
knockdown with a specific siRNA [41]. Additional studies
have demonstrated that the Chk1 inhibitor AZD7762
synergistically combined with numerous PARP1 inhibitors
(including olaparib, rucaparib or ABT888) to inhibit the
growth of mammary carcinoma cells in vitro and in vivo
[42,43]. In these studies, AZD7762 demonstrated little sin-
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Figure 6 V158411 potentiates the anti-tumor efficacy of cytotoxic chemotherapeutic drugs in vitro. A. Curves representing the 72 hour
antiproliferative effect of gemcitabine (left) or cisplatin (right) in MDA-MB-468 cells in combination with 0, 0.2 or 0.4 μM V158411. B. In vitro
potentiation of gemcitabine and cisplatin cytotoxicity by 0.1, 0.2, 0.4 or 0.8 μM V158411 in p53-proficient or p53-deficient breast cancer cell lines.
Potentiation factor was calculated by IC50(cytotoxic agent alone)/IC50(combination treatment). C. In vitro potentiation of carboplatin, oxaliplatin and cisplatin
cytotoxicity in SKOV-3 ovarian cancer cells by 0.1 μM V158411. The GI50 values are the average of 3 determinations ± SD with the potentiation
factor highlighted above each bar. D. SKOV-3 cells were treated with 250 μM carboplatin, 80 μM oxaliplatin or 20 μM cisplatin for 24 hours in the
presence of 0, 0.1 or 0.2 μM V158411 for 24 hours. The amount of Chk1 and H2AX phosphorylation was determined by western blotting.
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pers, only two overlapped with our study.
In light of these results, we attempted to understand
the mechanism by which single agent Chk1 inhibitors
induced TNBC and ovarian cancer cell death. The clearest
marker of response to Chk1 inhibition in all the sensitive
cell lines was the time dependent increase in phosphoryl-
ation of H2AX on serine 139. Phosphorylation on this site
is generally associated with an increase in DNA double
strand breaks [44]. Coupled with Chk1 inhibition reducing
cell viability and inducing caspase-3/7 dependent apop-
tosis and DNA fragmentation, cell death following Chk1
inhibition appears to be most likely via increased DNA
double strand breaks. The mechanism for the generation
of these breaks is not completely clear. However, since
Chk1 inhibition caused a dramatic decrease in the fraction
of cells in G1 that were unable to complete S-phase and
accumulate in mitosis suggests that replication fork col-
lapse and the subsequent formation of DSBs by the DNA
endonuclease Mus81/Eme1 [45] is responsible.
In all breast and ovarian cancer cell lines, including
those relatively resistant to V158411 single agent cyto-
toxicity, reduction in total Chk1 protein levels following
V158411 treatment was evident. This was especially no-
table at the higher concentrations of V158411 and ap-
peared to correlate with an increase in pH2AX (S139) in
the V158411 sensitive cell lines. V158411 treatment of
leukemia and lymphoma cell lines induced Chk1 degra-
dation that was proteasome dependent [38] whilst deg-
radation of Chk1 was observed in HT29 cells following
treatment with four structurally distinct Chk1 inhibitors
in combination with gemcitabine: V158411, LY2603618,
MK-8776 and GNE-900 [46]. Chk1 is deactivated through
protein degradation in response to replication and geno-
toxic stress. Phosphorylation of Chk1 at serine 317 and
345 by ATR promotes Chk1 activation but also induces
the ubiquitin-proteasome dependent degradation of Chk1
[47-49]. Given that V158411 induces phosphorylation of
Chk1 at serine 317 and 345 in breast and ovarian cancer
cells, this degradation of Chk1 reflects the normal homeo-
static mechanism of checkpoint resetting.
The precise mechanism for the sensitivity of the TNBC
and ovarian cancer cell lines compared to other solid
cancer cell lines remains to be fully understood. The
resistance of the two ER-positive breast cancer cell
lines BT474 and MCF-7 could not be overcome with
4-hydroxytamoxfien suggesting that estrogen receptor
signaling did not contribute to the relative sensitivities in
the breast cancer cell lines. Chk1 expression has been
demonstrated to be elevated in histological grade 3 TNBC
primary tumors compared to other grade 3 breast cancers
[50]. Sensitivity of the TNBC and ovarian cancer cell lines
did not correlate with total Chk1 protein expression levels
but did correlate closely with the levels of phosphorylationof Chk1 on serine 296 and to a lesser extent serine 317
but not with serine 345. This observation matched that
of Cole et al. [33] who identified neuroblastoma as a
potential therapeutic target for Chk1 inhibition and that
sensitivity to Chk1 inhibition by either siRNA or small
molecules correlated with Chk1 S296 phosphorylation.
The HER2 positive breast cancer cell line SKBr3 was ex-
tremely sensitive to growth inhibition by all three Chk1
inhibitors tested. Whilst this cell line had low levels of
Chk1 phosphorylation at serine 296, it was the only cell
line with high expression of pH2AX (S139) potentially
indicative of a reasonable level of DNA breakage in prolif-
erating cells. Shibata et al., [51] identified elevated expres-
sion levels of pChk1 (S317) and to a lesser extent pH2AX
(S139) as being predictive of the sensitivity of breast can-
cer cell lines to the Chk1 inhibitor PF-477736. Sensitivity
to V158411 appeared independent of both p53 and kRas
mutational status, both of which have previously been im-
plicated in Chk1’s mechanism of action [52]. The outlier
in this analysis was the ovarian cancer cell line ES-2. This
cell line had high expression levels of pChk1 (S296) but
was relatively resistant to growth inhibition by all three
Chk1 inhibitors. Further work is needed to understand the
relative resistance of this cell line to Chk1 inhibition.
The underlying mechanism for the sensitivity of these
cancer cell types to single Chk1 inhibitor therapy is not
yet clear and the phosphorylation events identified as
potential predictive markers of sensitivity (pChk1 (S296),
(S317) and pH2AX (S139)) are most likely symptomatic
rather than the cause of the underlying sensitivity. This
observation suggests that the molecular defects in these
cell lines occur in pathways for which Chk1 can mutu-
ally compensate to protect genomic integrity and there-
fore Chk1 inhibition is lethal. An example of this so far
discovered is the Fanconi’s Anemia (FA) DNA repair path-
way. Cells defective in FA were sensitive to Chk1 siRNA
and the small molecule Go6976 due to an accumulation
of unrepairable DNA double strand breaks [29]. The basal
like breast cancer cell line HCC9137 harbors a homozy-
gous truncation mutation in the DNA repair gene BRCA1
[53] and this reduced capacity to repair DNA breaks may
underlie this cell lines sensitivity. Underlying defects
in DNA repair would be predicted to confer increased
sensitivity to DNA damaging cytotoxic drugs such as
cisplatin. The correlation between sensitivity to cispla-
tin and V158411 was cell line dependent and not con-
sistent across the panel of breast and ovarian lines studied.
For example, the BRCA defective cell line HCC1937
was highly sensitive to cisplatin and V158411 whilst
the ovarian cell line SKOV-3 was equally sensitive to
V158411 but 8-fold more resistant to cisplatin than the
HCC1937 cell line. This suggests that different mecha-
nisms may account for the V158411 sensitivity in different
cell lines.
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cation or activation of oncogenic signaling pathways are
addicted to Chk1 kinase activity for the completion of a
normal S-phase [35,36]. The sensitivity of neuroblast-
oma and melanoma cell lines has been suggested to be
likely related to oncogenic replicative stress. In the case
of neuroblastoma, this has been linked to members of
the Myc family of oncogenes [33,34]. Therefore the sen-
sitivity of the breast and ovarian cell lines in this study
could be attributed to underlying defects in DNA repair
or DNA damage signaling pathways, oncogene induced
replicative stress or a combination of the two. Chk1 has
been demonstrated to be important for replication origin
firing, high rates of replication fork progression and rep-
lication fork stabilization [34,54,55]]. Inhibition of Chk1
may result in increased replication origin firing and re-
duced fork progression leading to increased regions of
RPA bound ssDNA. This in turn leads to ATR activation
and tumor cell apoptosis.
Triple-negative status was not a sufficient prognostic
marker for response to Chk1 inhibition as other cell line
types such as the HER2 positive SKBr3 breast cancer cell
line and SKOV-3 ovarian cancer cell line were among the
most sensitive cell lines to growth inhibition by V158411.
For this treatment to be better focused in the clinic to
those patients most likely to benefit then additional bio-
markers prognostic of sensitivity would be extremely be-
neficial. High expression of pChk1 (S296) in untreated
tumors and the induction of pH2AX (S139) post Chk1 in-
hibitor therapy appear to be the most sensitive and pre-
dictive markers for response to Chk1 inhibitor therapy.
However, phospho-protein profiling of tumor biopsies by
immunohistochemistry or western blotting is not without
its technical challenges. Alternative methods of identi-
fying potential clinical responders, such as gene signa-
ture profiles, would aid the use of Chk1 inhibitors as
monotherapy.
From this study and others, it is becoming clear that
Chk1 inhibitors may have clinical utility as a single agent
as well as in combination with cytotoxic chemotherapy
agents in a variety of human cancer types. Chk1 inhibi-
tors either as single agents or in combination with cyto-
toxic chemotherapy are a potentially viable therapeutic
option for the treatment of triple-negative breast cancer
in the clinic. High tumor expression of pChk1 (S296)
could serve as a useful biomarker to select those pa-
tients who would most likely benefit from Chk1 in-
hibitor therapy.
Conclusions
Clinical testing of Chk1 inhibitors is currently focused
on their ability to potentiate the anti-tumor efficacy of
cytotoxic chemotherapy drugs and anti-metabolite therap-
ies. Recent studies have demonstrated single agent activityof Chk1 inhibitors in cancer cells harboring defects in
DNA damage repair or response pathways or high levels
of replicative stress. V158411 either as a single agent or in
combination with cytotoxic chemotherapy are potentially
viable therapeutic options for the treatment of triple-
negative breast cancer in the clinic. High tumor expres-
sion of pChk1 (S296) could serve as a useful biomarker to
select those patients who would most likely benefit from
Chk1 inhibitor therapy. The BRCAness of triple-negative
breast cancer may underlie the sensitivity of this cancer
type to Chk1 inhibition.
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